Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

A 23-year-old male experienced good hair growth and increased self-confidence after 10 months of using oral finasteride (1.25mg) and topical minoxidil (5% twice a day), despite no decrease in hair shedding. He also used 1mm microneedling monthly and reported minor side effects like forgetfulness.

Dr. Toyos is recruiting more participants for a larger trial on hair loss treatments. The discussion mentions Minoxidil, finasteride, and RU58841 as potential treatments.

Scube3 trials have not started yet. Treatments discussed include Minoxidil, finasteride, and RU58841.

A 30-year-old male is experiencing some hair regrowth after 77 days using oral finasteride, topical minoxidil 5%, and a 0.5mm derma roller twice a week. Users note small hairs filling previously smooth spots, but it's too early to determine full regrowth potential.

A user shared their six-month progress using oral finasteride (1mg) and topical minoxidil (5%) for hair loss, with additional inconsistent microneedling. The combination showed noticeable improvement, and the user microneedles twice a week.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. UC Irvine scientists discover possible baldness cure.

The user is seeking a topical spray combining finasteride, minoxidil, and RU58841 or dutasteride due to side effects from oral treatments. They believe an all-in-one topical solution would be easier for long-term use.

The user experienced increased hair miniaturization and shedding despite using finasteride, topical minoxidil, microneedling, and other treatments. They are considering more aggressive treatments or a hair system if no improvement occurs by the end of 2025.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in Phase I trial, users seek group buy for research chemical.

A 23-year-old is using a topical 5% finasteride/minoxidil spray, microneedling, and taking biotin and vitamin D for hair regrowth, noticing slight improvement but still experiencing thinning. They are considering switching to oral finasteride but are concerned about potential side effects.

The post discusses a new hair loss treatment involving an improved pyri formula that has shown promising results, including thicker hair and a restored hairline, with minimal side effects. The author seeks investors to collaborate with Kintor or acquire the pyri patent, offering equity rewards and complimentary samples for verification.

A 25-year-old is using a combination of oral minoxidil, finasteride, RU58841, and topical dutasteride mixed with minoxidil to combat hair loss and hopes to see regrowth. They plan to update on the effectiveness of this regimen in a few months.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

A 36-year-old male has been using finasteride, 5% minoxidil foam, and microneedling with a 0.75mm dermastamp or Dr. pen for three months. He notices thicker hair and reduced hair loss, with high testosterone and normal DHT levels, while managing prolactin levels with vitamin B6.

PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.

A user's 7-month progress using 1 mg finasteride and topical minoxidil, with no side effects from the finasteride, achieving baby hairs on the hairline and other positive results. Other users have discussed different treatments such as microneedling and supplements, providing advice and encouragement to the poster.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.

A 23-year-old has been using finasteride every other day and topical minoxidil daily for five months to address hair thinning, with plans to resume dermarolling. They experienced minimal shedding and are considering switching to daily finasteride for better results.

The user added RU58841 to their finasteride and minoxidil routine, noticing significant improvement in hairline after 52 days. Some users warn about potential side effects of RU58841, while others express curiosity and congratulate the progress.

A user shared their hair regrowth progress after using minoxidil 5% twice daily since January 31 and adding oral dutasteride 0.5mg and minoxidil 2mg daily two weeks ago. They also used microneedling occasionally and are seeking opinions on potential further gains.

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

The conversation is about a user sharing their positive progress with hair regrowth using oral minoxidil, biotin, finasteride, and other supplements. The user also mentions using a HIMS oral fin/min combo and receives advice and encouragement from others.

The user shared minimal results from using JXL-069 for hair loss, noting a slight lengthening of vellus hairs and plans to switch to a prodrug variant due to limited effectiveness. They also mentioned using finasteride and minoxidil, which have plateaued in results.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

A user stopped finasteride due to side effects and rapid hair loss, considering a hair system. Others suggested alternatives like dutasteride, minoxidil, and topical finasteride.

The user does not respond well to minoxidil and is seeking an alternative to Tretinoin to upregulate sulfurtransferase activity for hair loss treatment. No specific alternative treatments were mentioned.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.